ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI CTEP-Approved Trials For the Month of February

February 28, 2014

FDA Employee Inspired to Compose an Anthem for the Agency.

August 4, 2006

Also in this 8-page issue: House Committee on Energy and Commerce is investigating the collapse of the Institute for Cancer Prevention, which owes $5.7 million to NCI.

December 3, 2004

Also: CALGB elects Schilsky to third term as chairman.

July 16, 2004

Klausner To Revamp NCI Budget Process To Make Categories Mean What They Say

December 8, 1995

In Brief: Ruddon To Head Eppley Institute; Shapiro elected ACR President; ACR Medalists Named

November 3, 1989